Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissionsJacalyn Rosenblatt, David Avigan, Richard M. Stone et al.|Science Translational Medicine|2016Cited by 165
Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host diseaseMyrna Nahas, Jacalyn Rosenblatt, Robert J. Soiffer et al.|Blood|2018Cited by 48
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.Boyu Hu, Susan O’Brien, Loretta J. Nastoupil et al.|Journal of Clinical Oncology|2024Cited by 19
Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic LeukemiaDimitrios Tzachanis, Robin Joyce, Ayad Hamdan et al.|Acta Haematologica|2014Cited by 18
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abataceptDivya Koura, Dimitrios Tzachanis, Kaitlyn C. Dykes et al.|Blood Advances|2025Cited by 7